Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOV1101-00
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
FOV1101-00 is an investigational low-dose cyclosporine (also known as cyclosporine A or CsA) formulation developed by Fovea Pharmaceuticals SA. It is designed for topical ocular administration as a solution in two strengths. The drug is being evaluated for its efficacy in patients with mild ongoing ocular allergic inflammation. Cyclosporine is an immunosuppressant that works by inhibiting calcineurin, thereby suppressing T-cell activation and reducing inflammation.
- Other names
- cyclosporinecyclosporine ACsA
02
Targets
CN (Calcineurin)Cyp (Cyclophilin family)
Beyond the preview
Go deeper on FOV1101-00.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOV1101-00.